HIV Treatment has been identified as one of four key strategies to Ending the HIV Epidemic in the United States. Antiretroviral therapy (ART) to treat HIV has evolved significantly since the advent of potent combination therapy in 1996. Most recently, there has been a shift toward 2-drug regimens as clinical studies have demonstrated these regimens can be comparable to more traditional 3-drug combinations, a shift that is being propelled further by patient and provider interest in novel long-acting injectable 2-drug therapy. The HRSA-funded National Clinician Consultation Center (NCCC) provides free, confidential, one-on-one teleconsultation to health care providers on key HIV treatment recommendations, including determining when and in whom two-drug antiretroviral therapy should be considered. Based on real cases, we will review the nuts and bolts of currently recommended two-drug ART options for HIV treatment, including data from clinical trials and the potential benefits and limitations of this approach, and share ideas on how this strategy can be integrated with other treatment approaches to improve equitable access to treatment for key populations.
At the end of this presentation, participants will be able to:
- Describe the evolution of 2-drug antiretroviral regimens (dual therapy).
- Recognize clinical scenarios where dual therapy can be used.
- Describe the NCCC’s approach to supporting clinicians treating patients with HIV
- List potential limitations of dual therapy.
Dr. Jason Tokumoto